GIFT NIFTY 25253.00 [-0.21%]     DOW JONES FUTURES 40545.79 [0.78%]     NASDAQ 17990.50 [0.38%]     FTSE 100 9243.29 [0.18%]     NIKKEI 225 45493.66 [0.99%]     HANG SENG 26159.12 [-0.70%]     SHANGHAI 3821.83 [-0.18%]     ASX 200 8146.65 [0.00]    
INDUSINDBK↑2.86% [20.95]     AXISBANK↑2.31% [26.4]     BAJFINANCE↑1.89% [19]     JSWSTEEL↑1.83% [20.4]     SBIN↑1.80% [15.35]     MARUTI↑1.78% [281]     SAMMAANCAP↓-4.35% [-6.14]     TECHM↓-2.23% [-33.5]     SBILIFE↓-2.07% [-38.3]     BRITANNIA↓-2.00% [-120.5]     ULTRACEMCO↓-1.97% [-249]     HINDUNILVR↓-1.95% [-50]    

Latest Stock Market News

Mukesh Ambani s Reliance Industries is embarking on ambitious ventures in AI and FMCG, aiming for significant growth. Reliance Intelligence, a joint venture with Meta and Google, seeks to dominate India s AI landscape. Simultaneously, Reliance Consumer Products targets a staggering ₹1 lakh crore revenue within five years, challenging established FMCG players through strategic acquisitions and brand building.

Rate this item

(1 Vote)

US private equity firm KKR has joined the formal sale process of British real estate investment trust PRS REIT. Property investor Long Harbour already made a bid. KKR has not yet made a bid. Long Harbour s takeover proposal remains at 631.6 million pounds. PRS focuses on family homes in the private rented sector.

Rate this item

(1 Vote)

Mindspace Business Parks REIT is targeting a 50% increase in net operating income in the next three to four years, driven by a Rs 4,200 crore expansion plan to add 8 million sq ft. The company anticipates its NOI to grow by Rs 900-1,000 crore, leveraging India s cost advantages and the growing demand from tech companies and global capability centers.

The housing market is shifting, giving buyers more leverage as rising inventory and affordability concerns pressure sellers to negotiate. While national listing prices saw a slight increase in July, some metro areas are experiencing price declines. Sellers are offering concessions like price reductions and covering closing costs to attract buyers in a market where homes are lingering longer.

Airbnb s presence in India significantly boosted the economy in 2024, supporting 1.11 lakh jobs and contributing Rs 2,400 crore in wages. Guest spending reached Rs 11,200 crore, with domestic travelers making up 91% of guests. The platform s activity accounted for 0.5% of India s travel and tourism GDP, demonstrating its growing impact on the nation s hospitality sector and allied industries.

Indian stock market analysts suggest a positive outlook for the week, fueled by GST benefits and the approaching festive season. Brokerages recommend buying shares of Arisinfra Solutions, Navin Fluorine, Nykaa, and RIL. Further recommendations include IREDA and Power Grid, citing recent gains and project wins.

Rate this item

(1 Vote)

Amanta Healthcare shares: Amanta Healthcare shares debuted with a premium, listing at Rs 135 on NSE and Rs 134 on BSE against an issue price of Rs 126. The Rs 126 crore IPO, a fresh issue, will fund expansion, including a new SteriPort line. Despite strong demand and oversubscription, analysts consider the IPO "fully priced," citing a high price-to-earnings ratio.

Three IPOs, Urban Company, Shringar House of Mangalsutra, and Dev Accelerator, are opening. Urban Company, a home services marketplace, aims to raise significant capital. Shringar focuses on mangalsutras, targeting steady earnings. Dev Accelerator offers flexible workspace solutions, eyeing expansion. Analysts suggest Dev Accelerator for listing gains. Urban Company is considered for long-term potential.

Gold futures on MCX soared to a record high of Rs 1,09,000/10 grams, fueled by expectations of aggressive US Fed rate cuts. Silver futures also remained firm, while international spot gold hit an all-time high of $3,646.53/oz. Weak U.S. job data has increased the likelihood of these rate cuts, weakening the dollar and supporting precious metal prices.

Glenmark Pharmaceuticals shares surged following its subsidiary s $700 million upfront payment from AbbVie for an exclusive licensing agreement concerning IGI s lead drug candidate, ISB 2001. The deal grants AbbVie rights in key markets, while Glenmark retains commercialization in emerging regions.

Warning! Information Posting in this website is only for educational purpose. We are not responsible for losses incurred in Trading based on this information.